Blue Earth receives approval for PET tracer for prostate cancer

By staff writers

June 2, 2023 -- The U.S. Food and Drug Administration (FDA) has approved Blue Earth Diagnostics' F-18 rhPSMA-7.3 PET radiotracer for detecting prostate cancer.

F-18 rhPSMA-7.3 (Posluma) is indicated for men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence. The tracer is a radiohybrid agent consisting of a prostate-specific membrane antigen (PSMA) ligand that may be combined with isotopes such as F-18 for imaging purposes or lutetium-177 or actinium-225 for therapeutic use.

Posluma will be commercially available in early June 2023 and will become increasingly available nationally in coming months, the company said.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking